Indegene IPO Details
| IPO Size | 1841.76 |
| Price Range | ₹430 to ₹452 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 33 |
| Investment (cut-off price) | ₹14,916 |
| Pre IPO Promotor Holding | 30.71% |
| Post IPO Promotor Holding | -- |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Indegene IPO Timelines
06/05/2024
Start Date08/05/2024
End Date10/05/2024
Refund Initiation10/05/2024
Credit of Shares to Demat Ac13/05/2024
Listing DateIndegene IPO Lot Size
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 33 | ₹14,916 |
| Retail Maximum | 13 | 429 | ₹193,908 |
| S-HNI Minimum | 14 | 462 | ₹208,824 |
| B-HNI Minimum | 68 | 2244 | ₹1,014,288 |
Indegene IPO Subscription Status
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 197.55 x | 55.07 x | 7.95 x | 6.48 x | 69.91 x |
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹655 | ₹570.90 | ₹660 | ₹527 |
Indegene IPO Company Financials
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2021 | ₹996.92 | ₹768.25 | ₹149.41 |
| FY 2022 | ₹1690.50 | ₹1417.10 | ₹162.82 |
| FY 2023 | ₹2364.10 | ₹2001.05 | ₹266.10 |
| FY 2024 (9M) | ₹1969.75 | ₹1644.64 | ₹241.90 |
About Company
Indegene Limited provides digital-led commercialization services for the life sciences industry, specifically catering to biopharmaceutical, emerging biotech and medical devices companies. The company assistance in drug development, clinical trials, pharmacovigilance, regulatory submissions, complaints management, and sales/marketing.
The company’s solutions enable its client companies to develop and sell products through their life cycle in a more effective, efficient and modern manner. The company offers Enterprise Commercial Solutions and Omnichannel Activation solutions to address the commercial needs of life sciences companies. It also offers Enterprise Medical Solutions and Enterprise Clinical Solutions to support the medical and R&D functions of its client companies.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 1998 | Healthcare | Manish gupta |
Know Before Investing
Indegene IPO Strengths
- The company has domain expertise in healthcare.
- It also has digital capabilities and an in-house developed technology portfolio.
- It has a track record of establishing long-standing client relationships.
- It has 17 offices located across North America, Europe and Asia.
- The company has experience in creating value through acquisitions.
Indegene IPO Risks
- A majority of their revenues are derived from their Subsidiaries.
- The life sciences operations industry is highly competitive
- The company derives a majority portion of its revenues from large clients located in North America and Europe.
Swot Analysis for Indegene IPO
Strengths
Weaknesses
Opportunities
Threats
Contact Details of IXIGO
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: [email protected]
Website: https://linkintime.co.in/initial_offer/public-issues.html
Company Details
Indegene Limited
Aspen Block G4, 3 rd Floor, Manyata Embassy
Business Park, Outer Ring Road, Nagawara
Bengaluru 560 045
Phone: +91 80 4674 4567
Email: [email protected]
Website: https://www.indegene.com/
IPO Registar Details
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: [email protected]
Website: https://linkintime.co.in/initial_offer/public-issues.html
FAQs
The key objectives of Indegene Ltd. IPO are:
- Repayment/prepayment of indebtedness of one of their Material Subsidiaries, ILSL Holdings, Inc.
- Funding the capital expenditure requirements of their Company and one of their Material Subsidiaries, Indegene, Inc.
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory And Securities (India) Pvt Ltd are the book-running lead managers for the Indegene Ltd. IPO.